Name | PU-H71 |
Description | PU-H71 is an effective selective HSP90 inhibitor with an IC50 of 51 nM. |
In vitro | PU-H71(1 μ M) potently inhibits the growth of triple negative breast cancer (TNBC) cell lines MDA-MB-468, MDA-MB-231, and HCC-1806, with IC50 values of 65, 140, and 87 nM, respectively. PU-H71(1 μ M) kills 80%, 65%, and 80% of MDA-MB-468, MDA-MB-231, and HCC-1806 cells, respectively[1]. |
In vivo | MDA-MB-231 model treated with PU-H71 at a dose of 75 mg/kg was 100% fully effective. After 37 days of treatment, tumor was replaced by scar tissue, accompanied by a reduction in many proliferative and anti apoptotic molecules, such as EGFR, HER3, Raf-1, Akt, and p-Akt, which decreased by 80%, 95%, 99%, 80%, and 65%, respectively. PU-H71 (75 mg/kg, three times a week) inhibits tumor growth by 96%, reduces tumor cell proliferation by 60%, decreases activated Akt associated with survival and high invasive potential by 85%, and increases apoptosis by 6-fold[1]. |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 46.1 mg/mL (89.9 mM)
|
Keywords | PU-H71 | PUH71 | PU H71 |
Inhibitors Related | Ethoxyquin | SNX0723 | Tamoxifen | DN401 | SNX2112 | Ganetespib | Teprenone | Elesclomol | Rifabutin | Palmitic acid | Paeoniflorin | Tamoxifen Citrate |